In silico investigation on alkaloids of Rauwolfia serpentina as potential inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase

• Published in: Saudi journal of biological sciences Vol. 28; no. 1; pp. 731 - 737
• Main Authors: Azmi, Muhammad Bilal, Sultana, Saleha, Naeem, Sadaf, Qureshi, Shamim Akhtar
• Format: Journal Article
• Language: English
• Published: Saudi Arabia Elsevier B.V 01.01.2021; Elsevier
• Subjects: Alkaloids; Hypercholesterolemia; In silico; Molegro Virtual Docker; Original; Rauwolfia serpentina; Alkaloids; In silico; Hypercholesterolemia; Rauwolfia serpentina; Molegro Virtual Docker
• ISSN: 1319-562X; 2213-7106
• DOI: 10.1016/j.sjbs.2020.10.066

Present work aimed to investigate the in silico activity of the alkaloids of roots of Rauwolfia serpentina as inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR). For this purpose, the three-dimensional (3D) structure of the protein HMGCR (PDB ID: 1HW9) was downloaded from Protein Data Bank (PDB) database, as a target enzyme. The structures of twelve alkaloids from the roots of R. serpentina were selected as ligands and docked with the selected HMGCR enzyme using Molegro Virtual Docker (MVD) software. The software ‘MVD’ computes the binding (atom) energies of selected protein (enzyme) and each ligand at minimum energetic conformation state by using the PLP (Piecewise Linear Potential) scoring mechanism. Docking results of twelve tested alkaloids showed that five alkaloids including compound 1 (ajmalicine), 2 (reserpine), 3 (indobinine), 4 (yohimbine), and 5 (indobine) have displayed the highest MolDock scores and best fit within the prominent active site residues (positioned between 684 and 692 of cis-loop) of HMGCR. According to the lowest MolDock energies obtained through non-covalent interactions of alkaloids with HMGCR, these are characterized to be the potential inhibitors of HMGCR. Therefore, the alkaloids from R. serpentina can effectively suppress the cholesterol biosynthesis pathway through inhibition of HMGCR and can serve as potential lead compounds for the development of new drugs for the treatment of hyperlipidaemia.